• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      Understanding and addressing unmet need in Urology: Overactive bladder (OAB)

      OAB is a highly prevalent, chronic condition5

      • Approximately 1 in 6 individuals aged ≥40 years have symptoms of OAB
      • Prevalence in men is similar to prevalence in women (15.6% and 17.4%, respectively)
      • Prevalence increases with age

      Adapted from Milsom et al, 20015


      What drives a patient to see a doctor?


      OAB  is a complex, multi-symptom syndrome that can be difficult to treat, requiring appropriate effective management - including treatment or referrals to improve patient outcomes6,7

      Definition of OAB

      Understanding the sensation of urgency


      ICS definitions: incontinence8,10

      • Urgency urinary incontinence (UUI) is the complaint of involuntary leakage accompanied by or  immediately preceded by urgency
      • Stress urinary incontinence (SUI) is the complaint of involuntary leakage on effort or exertion,  or on sneezing or coughing
      • Mixed urinary incontinence (MUI) is the complaint of involuntary leakage associated with urgency  and also with exertion, effort, sneezing or coughing

      OAB can significantly impair patients' quality of life (QoL) when not treated effectively6,7

      Impact of OAB on QoL (SF-36) vs the general population11

      Adapted from Abrams et al, 200011


      OAB  is a complex, multi-symptom syndrome that can be difficult to treat, requiring appropriate effective management - including treatment or referrals to improve patient outcomes6,7

      ICS: International Continence Society;  MUI: mixed urinary incontinence; OAB: overactive bladder; QoL: quality of life; SUI: stress urinary incontinence; UUI: urgency urinary incontinence.

      BOTOX® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, urgency and frequency.12

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
      4. Allergan Ltd. Data on file 014
      5. Milsom I, Abrams P et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87(9):760-766
      6. Starkman J S, Smith C P and Staskin D R. Surgical options for drug-refractory overactive bladder patients. Reviews in Urology 2010;12(2-3):e97
      7. Stewart W, Van Rooyen J et al. Prevalence and burden of overactive bladder in the United States. World journal of Urology 2003;20(6):327-336 
      8. Abrams P, Cardozo L et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21(2):167-178
      9. Milsom I. Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal (AI) incontinence. Abrams P et al. Incontinence: 6th edition. 2017:50
      10. Haylen B T, De Ridder D et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourology and Urodynamics: Official Journal of the International Continence Society 2010;29(1),4-20
      11. Abrams P, Kelleher C J et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000;6(11 Suppl):S580-590
      12. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed April 2022

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      Date of preparation: April 2022. UK-BUO-220007.